DUPIXENT simultaneously improved asthma control (ie, reducing severe exacerbations, improving lung function) while reducing or eliminating steroid use in the ITT population at Week 24 (VENTURE, no biomarker requirement, secondary endpoints).

Learn more about how DUPIXENT may impact OCS use